









Markets
/
Stocks
/
nasdaq-xtlb
/

X T L Biopharmaceuticals Ltd

XTLB

1.208USD

-0.032-2.62%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

10.64MMarket Cap

LossP/E TTM



X T L Biopharmaceuticals Ltd

1.208

-0.032-2.62%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Despite an average stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

281 / 506

Overall Ranking

471 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

XTL Biopharmaceuticals Ltd is an Israel-based biopharmaceutical company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.

Growing

The company is in a growing phase, with the latest annual income totaling USD 451.00K.

Fairly Valued

The company’s latest PE is -7.89, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 3.90M shares, increasing 43.40% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 4.49, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

4.49

Change



Financials

4.63

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

4.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.81

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

5.00

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -8.10, which is -66.62% below the recent high of -2.71 and -28.87% above the recent low of -10.44.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 281/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.42, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.47 and the support level at 1.05, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.42

Change

-0.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.002

Neutral

RSI(14)

45.480

Neutral

STOCH(KDJ)(9,3,3)

22.781

Sell

ATR(14)

0.115

High Vlolatility

CCI(14)

-43.633

Neutral

Williams %R

76.220

Sell

TRIX(12,20)

-0.337

Sell

StochRSI(14)

31.540

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.214

Sell

MA10

1.292

Sell

MA20

1.244

Sell

MA50

1.420

Sell

MA100

1.321

Sell

MA200

1.411

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Rabinovitch (Alexander)

1.46M

+120.96%

Klinger (Roy)

862.29K

Klinger (Tal)

862.29K

Yaacobi (Yaron)

450.00K

Noked Capital Ltd.

198.89K

Rhumbline Advisers Ltd. Partnership

10.95K

Morgan Stanley & Co. LLC

13.25K

-27.79%

Geode Capital Management, L.L.C.

8.90K

Turgeman (Doron)

3.40K

UBS Financial Services, Inc.

-100.00%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.91, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.